Investigational drug · Phase 2
BRL-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Beta-Thalassemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "BRL-101"
First trial start
2022
Nov 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRL-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Beta-Thalassemia
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BRL-101" as an intervention, largest first.
- Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaActive, not recruiting
Bioray LaboratoriesIndustry
NCT05577312 · 39 participants · Start Nov 2, 2022 · Primary completion Oct 20, 2026
Drug: BRL-101 · For: Beta-Thalassemia
Sites: Guangzhou, China; Guanzhou, China; Shenzhen, China · 7 sites in all
Bioray LaboratoriesIndustry
NCT06287099 · 5 participants (planned) · Start Apr 20, 2024 · Primary completion Oct 20, 2025
Drug: BRL-101 · For: Sickle Cell Disease
- Clinical Study of BRL-101 in Severe SCDStatus unknown
Bioray LaboratoriesIndustry
NCT06300723 · 3 participants (planned) · Start Jul 29, 2024 · Primary completion Mar 20, 2026
Drug: BRL-101 · For: Sickle Cell Disease
Sites: Nanning, China
- Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell DiseaseStatus unknown
Bioray LaboratoriesIndustry
NCT06287086 · 1 participants (planned) · Start Jun 14, 2024 · Primary completion Aug 20, 2025
Drug: BRL-101 autologous hematopoietic stem and progenitor cells injection · For: Sickle Cell Disease
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Beta-Thalassemia
- Vebeglogene autotemcelBeta-globin lentiviral vector transduced autologous HSPCsPhase 21 trial
Lantu Biopharma · Beta-Thalassemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.